These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 32500668)
1. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab. Schreiber S; Yamamoto K; Muniz R; Iwura T Pharmacol Res Perspect; 2020 Jun; 8(3):e00604. PubMed ID: 32500668 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects. Puri A; Niewiarowski A; Arai Y; Nomura H; Baird M; Dalrymple I; Warrington S; Boyce M Br J Clin Pharmacol; 2017 Jul; 83(7):1405-1415. PubMed ID: 28133772 [TBL] [Abstract][Full Text] [Related]
4. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®. Magnenat L; Palmese A; Fremaux C; D'Amici F; Terlizzese M; Rossi M; Chevalet L MAbs; 2017 Jan; 9(1):127-139. PubMed ID: 27854156 [TBL] [Abstract][Full Text] [Related]
5. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935 [TBL] [Abstract][Full Text] [Related]
6. Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab. Liu J; Eris T; Li C; Cao S; Kuhns S BioDrugs; 2016 Aug; 30(4):321-38. PubMed ID: 27461107 [TBL] [Abstract][Full Text] [Related]
7. Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. Genovese MC; Kellner H; Arai Y; Muniz R; Alten R RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371430 [TBL] [Abstract][Full Text] [Related]
8. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Genovese MC; Glover J; Greenwald M; Porawska W; El Khouri EC; Dokoupilova E; Vargas JI; Stanislavchuk M; Kellner H; Baranova E; Matsunaga N; Alten R Arthritis Res Ther; 2019 Dec; 21(1):281. PubMed ID: 31831079 [TBL] [Abstract][Full Text] [Related]
9. Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira Lee JJ; Yang J; Lee C; Moon Y; Ahn S; Yang J Biologicals; 2019 Mar; 58():7-15. PubMed ID: 30744947 [TBL] [Abstract][Full Text] [Related]
10. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar. Cerutti ML; Pesce A; Bès C; Seigelchifer M BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214 [TBL] [Abstract][Full Text] [Related]
11. Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira). Gao D; Nie L; Yuan J; Hu F; Wu Z; Lin Q; Wang H J Pharm Sci; 2022 Apr; 111(4):1142-1151. PubMed ID: 34863972 [TBL] [Abstract][Full Text] [Related]
12. Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications. Kronthaler U; Fritsch C; Hainzl O; Seidl A; da Silva A Expert Opin Biol Ther; 2018 Aug; 18(8):921-930. PubMed ID: 29962245 [TBL] [Abstract][Full Text] [Related]
13. Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab. Velayudhan J; Chen YF; Rohrbach A; Pastula C; Maher G; Thomas H; Brown R; Born TL BioDrugs; 2016 Aug; 30(4):339-51. PubMed ID: 27422671 [TBL] [Abstract][Full Text] [Related]
14. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira. McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743 [TBL] [Abstract][Full Text] [Related]
15. Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®). Kwon JC; Kwon OH; Jeong RU; Kim N; Song S; Choi I; Lee J; Horiuchi T Anim Cells Syst (Seoul); 2021; 25(3):182-194. PubMed ID: 34262661 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP Jeong YR; Jeong RU; Son JH; Kwon JC; Jung S; Song MA; Hwang JA; Lee GM BioDrugs; 2018 Apr; 32(2):153-168. PubMed ID: 29556960 [TBL] [Abstract][Full Text] [Related]
17. Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab. Jiang Y; Arora T; Klakamp S; Davis J; Chandrasekher YA; Young G; Du Y; Yu B; Miller KJ Drugs R D; 2023 Dec; 23(4):377-395. PubMed ID: 37632627 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab. Lee N; Lee JJ; Yang H; Baek S; Kim S; Kim S; Lee T; Song D; Park G MAbs; 2019 Jan; 11(1):129-144. PubMed ID: 30296198 [TBL] [Abstract][Full Text] [Related]
19. Quality by Design-Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®. Zhang E; Xie L; Qin P; Lu L; Xu Y; Gao W; Wang L; Xie MH; Jiang W; Liu S AAPS J; 2020 May; 22(3):69. PubMed ID: 32385732 [TBL] [Abstract][Full Text] [Related]
20. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects. Bush J; Kawakami K; Muniz R BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]